Background . Incorporation of a poly-ε-caprolactone (PCL) scaffold in circular stapled anastomoses has been shown to increase the anastomotic tensile strength on postoperative day (POD) 5 in a pig model. The aim of this study was to investigate the effects of incorporation of a PCL scaffold in a circular stapled end-to-end small intestine anastomosis, with stricture formation and anastomotic histology as primary outcomes in a 30-day observation period. Methods . A total of 15 piglets were included. In each piglet, three circular stapled end-to-end anastomoses were made in the small intestines. Two were interventional and one was a control. On POD 10, 20, or 30, the anastomoses were subjected to in vivo intraluminal contrast study, and the index for anastomotic lumen was calculated. The anastomotic segment was resected and subjected to a tensile strength test and histological examination. Results . At POD 10, the mean ± SD value for anastomotic index was .749 ± .065 in control anastomoses and .637 ± .051 in interventional anastomosis ( P = .0046), at POD 20, .541 ± .150 and .724 ± .07 ( P = .051), and at POD 30, .645 ± .103 and .686 ± .057 ( P = .341), respectively. No significant difference was observed in maximum tensile strength and histology at POD 30. Conclusions . The incorporation of a PCL scaffold in a circular stapled end-to-end small intestine anastomosis does not increase the risk of stricture or impair wound healing after 30 days.
Importance Intraventricular hemorrhage (IVH) is associated with high morbidity and mortality. A strong need exists for treatment advances. IRRAflow was recently introduced as a method for minimally invasive, controlled, and accelerated IVH wash-out. However, no current evidence supports this technology. Here, we present the first pivotal safety/efficacy evaluation in a randomized controlled setting. Objective To evaluate the safety and efficacy of active hematoma irrigation using the IRRAflow device compared with standard external ventricular drainage (EVD) for the IVH treatment. Design, setting, and participants This investigator-initiated, prospective multi-center, 1:1 randomized, single-blinded, clinical trial was conducted at the Aarhus University Hospital and Odense University Hospital in Denmark from January 13, 2022 to November 24, 2022. The trial was set to include 58 IVH patients with prespecified interim analysis at final endpoint collection for the first 20 patients. Interventions Patients were randomized to receive either IRRAflow or standard EVD treatment. The IRRAflow performs periodic active irrigation and aspiration contrary to standard passive gravity-driven EVD. Main outcomes and measures Outcomes were chosen to reflect key IRRAflow value propositions. The primary outcome was rate of catheter occlusions. The main outcome of the prespecified interim analysis was risk of severe adverse events (SAEs). Secondary outcomes were hematoma clearance rate, shunt dependency rate, procedure time for primary catheter placement, length of intensive care unit (ICU) stay, treatment duration, functional outcome (modified Rankin Scale (mRS) and extended Glasgow Outcome Scale (eGOS)) 90 days after inclusion, adverse events (AEs) (including catheter-related infections and procedure-related complications), and overall survival. Results The study was terminated early due to a significantly increased risk of SAEs in the IRRAflow group compared with EVD (risk difference = 0.43, 95% confidence interval (CI) (0.059;0.813), p=0.044), incidence rate ratio divided by person time = 6.0, 95%CI 1.38-26.11) p=0.012). The catheter occlusion rate was 37.5% in the IRRAflow group versus 6.6% in the EVD group (p=0.141), which met the prespecified 0.2 alpha level. The median procedure time for primary catheter placement was 53.5 min compared with 12 min in the control group (p=0.0001). No significant difference was observed for other secondary outcomes. The majority of SAEs had a causal relationship with the intervention. Conclusion and relevance We found that the current IRRAflow treatment is encumbered by a significantly increased number of SAEs. We recommend caution when using the device. Based on root-cause analysis, our recommendation is that a number of changes be implemented to improve the safety of the device in IVH treatment. We believe that our results are pivotal in ensuring the future safety of patients with IVH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.